ADVANCED PANCREATIC ADENOCARCINOMA
Clinical trials for ADVANCED PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…
Matched conditions: ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail tested for tough pancreatic cancer
Disease control CompletedThis early-phase study tested a combination of three drugs (gemcitabine, capecitabine, and erlotinib) in 30 people with advanced pancreatic cancer that had already been treated. The main goal was to find the safest dose and understand side effects. This is not a cure, but aims to…
Matched conditions: ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for pancreatic cancer: targeted drug shows promise in early trial
Disease control CompletedThis study tested a drug called niraparib in 32 people with advanced pancreatic cancer that has certain gene changes (like BRCA). The goal was to see if the drug could slow down or stop the cancer from growing. While not a cure, it offers a targeted treatment option for patients …
Matched conditions: ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Matched conditions: ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Vitamin d and malaria drug join forces against pancreatic cancer
Disease control CompletedThis phase II trial tested whether adding paricalcitol (a vitamin D drug) and hydroxychloroquine (an autophagy inhibitor) to standard chemotherapy could help shrink tumors in 10 people with advanced or metastatic pancreatic cancer. The goal was to see if the combination improved …
Matched conditions: ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC